Cargando…

Biomarkers and severe asthma: a critical appraisal

Severe asthma (SA) is a clinically and etiologically heterogeneous respiratory disease which affects among 5–10 % of asthmatic patients. Despite high-dose therapy, a large patients percentage is not fully controlled and has a poor quality of life. In this review, we describe the biomarkers actually...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiappori, Alessandra, De Ferrari, Laura, Folli, Chiara, Mauri, Pierluigi, Riccio, Anna Maria, Canonica, Giorgio Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590266/ https://www.ncbi.nlm.nih.gov/pubmed/26430389 http://dx.doi.org/10.1186/s12948-015-0027-7

Ejemplares similares

Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months
por: Riccio, Anna Maria, et al.
Publicado: (2017)

CD4(+)CD25(high)CD127(-) regulatory T-cells in COPD: smoke and drugs effect
por: Chiappori, Alessandra, et al.
Publicado: (2016)

Severe asthma: One disease and multiple definitions
por: Bagnasco, Diego, et al.
Publicado: (2021)

Poster 1002: Galectin-3 as predictive biomarker of airways remodeling modulation in omalizumab treated severe asthma patients
por: Mauri, Pierluigi, et al.
Publicado: (2014)

Plasma Galectin-3 and urine proteomics predict FEV(1) improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study()
por: Riccio, Anna Maria, et al.
Publicado: (2020)

A critical appraisal on AIT in childhood asthma
por: Ferrando, Matteo, et al.
Publicado: (2018)

Critical evaluation of asthma biomarkers in clinical practice
por: Guida, Giuseppe, et al.
Publicado: (2022)

Targeted therapy in severe asthma today: focus on immunoglobulin E
por: Pelaia, Girolamo, et al.
Publicado: (2017)

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
por: Crimi, Claudia, et al.
Publicado: (2023)

Personalized Approach to Severe Asthma
por: Heffler, Enrico, et al.
Publicado: (2018)

Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI
por: Senna, Gianenrico, et al.
Publicado: (2020)

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
por: Puggioni, Francesca, et al.
Publicado: (2020)

Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis
por: Canonica, Giorgio Walter, et al.
Publicado: (2021)

Therapeutic interventions in severe asthma
por: Canonica, Giorgio Walter, et al.
Publicado: (2016)

Overcoming Barriers to the Effective Management of Severe Asthma in Italy
por: Paggiaro, Pierluigi, et al.
Publicado: (2021)

Interleukin-5 in the Pathophysiology of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2019)

Is allergic sensitization relevant in severe asthma? Which allergens may be culprit?
por: Lombardi, Carlo, et al.
Publicado: (2017)

Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study
por: Canonica, Giorgio Walter, et al.
Publicado: (2015)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
por: Bagnasco, Diego, et al.
Publicado: (2023)

A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM)
por: Menzella, Francesco, et al.
Publicado: (2021)

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
por: Canonica, Giorgio Walter, et al.
Publicado: (2020)

Biomarkers for Lupus Nephritis: A Critical Appraisal
por: Mok, Chi Chiu
Publicado: (2010)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
por: Canonica, Giorgio Walter, et al.
Publicado: (2021)

Psychological aspects in asthma: do psychological factors affect asthma management?
por: Baiardini, Ilaria, et al.
Publicado: (2015)

Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal
por: Chapman, Kenneth R, et al.
Publicado: (2010)

Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
por: Heffler, Enrico, et al.
Publicado: (2020)

Treatment strategies for asthma: reshaping the concept of asthma management
por: Papi, Alberto, et al.
Publicado: (2020)

Allergen immunotherapy in asthma; what is new?
por: Passalacqua, Giovanni, et al.
Publicado: (2015)

Type 2 immunity in asthma
por: Caminati, Marco, et al.
Publicado: (2018)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
por: Solidoro, Paolo, et al.
Publicado: (2019)

Asthma research and practice: a new journey begins
por: Celedon, Juan C., et al.
Publicado: (2015)

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
por: Pini, Laura, et al.
Publicado: (2021)

The WEB-based Asthma Control: an intriguing connection or a dangerous hazard?
por: Lombardi, Carlo, et al.
Publicado: (2015)

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
por: Canonica, Giorgio Walter, et al.
Publicado: (2019)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
por: Solidoro, Paolo, et al.
Publicado: (2022)

Critical appraisal of the literature
por: FERREIRA, ÁLIDA ROSÁRIA SILVA, et al.
Publicado: (2021)

Biologics in severe asthma: the role of real-world evidence from registries
por: Paoletti, Giovanni, et al.
Publicado: (2022)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
por: Canonica, Giorgio Walter, et al.
Publicado: (2018)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair(®) In the Management of Asthma) study
por: Colombo, Delia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ot95nt7rd3ep7tsn7j0l9f6hgc